Will new weight loss drugs save or bankrupt the NHS?
New weight loss drugs known commercially as Wegovy and Mounjaro have been demonstrated to have a big effect in helping people to lose weight, and have recently been approved for use in obesity treatment in the NHS in England. In total, 4.1 million people would meet the criteria to be eligible to take one of these drugs. That seems fantastic - an end to obesity in our time. The problem is can we afford these drugs without bankrupting the NHS? How badly do we need them? But will this work? Should we be more ambitious? Can this help the NHS? Or bankrupt it? Guests: John Wilding, Professor of Medicine at The University of Liverpool. Alfie Slade is Government Affairs Lead at the Obesity Health Alliance Naveed Sattar, Professor of Metabolic Medicine at the University of Glasgow. Daniel Susskind, Research Professor in Economics at King's College, London. Dr Ellen Fallows, GP and Vice-President of The British Society of Lifestyle Medicine.Presenter: David Aaronovitch Producers: Charlotte McDonald, Kirsteen Knight and Beth Ashmead Latham Sound engineers: Rod Farquhar, Neva Missirian Editor: Richard Vadon Production Co-ordinator: Gemma Ashman